nodes	percent_of_prediction	percent_of_DWPC	metapath
Nilotinib—EPHA3—cleft lip	0.746	1	CbGaD
Nilotinib—MAPK8—periosteum—cleft lip	0.00683	0.0918	CbGeAlD
Nilotinib—MAPK8—cartilage tissue—cleft lip	0.00479	0.0643	CbGeAlD
Nilotinib—CA6—ear—cleft lip	0.00338	0.0453	CbGeAlD
Nilotinib—CA3—ear—cleft lip	0.0032	0.0429	CbGeAlD
Nilotinib—CSF1R—periosteum—cleft lip	0.00314	0.0422	CbGeAlD
Nilotinib—Ponatinib—FGFR3—cleft lip	0.00286	0.387	CrCbGaD
Nilotinib—Ponatinib—FGFR1—cleft lip	0.00227	0.307	CrCbGaD
Nilotinib—Ponatinib—FGFR2—cleft lip	0.00227	0.307	CrCbGaD
Nilotinib—EPHA4—tongue—cleft lip	0.00199	0.0267	CbGeAlD
Nilotinib—MAPK8—mouth—cleft lip	0.00194	0.0261	CbGeAlD
Nilotinib—CA2—periosteum—cleft lip	0.00169	0.0227	CbGeAlD
Nilotinib—EPHB2—telencephalon—cleft lip	0.00141	0.0189	CbGeAlD
Nilotinib—CA6—mouth—cleft lip	0.0014	0.0188	CbGeAlD
Nilotinib—MAPK8—embryo—cleft lip	0.00139	0.0186	CbGeAlD
Nilotinib—EPHA4—mouth—cleft lip	0.00134	0.018	CbGeAlD
Nilotinib—CA3—mouth—cleft lip	0.00132	0.0178	CbGeAlD
Nilotinib—MAPK11—telencephalon—cleft lip	0.00126	0.0169	CbGeAlD
Nilotinib—CDC42BPB—telencephalon—cleft lip	0.00125	0.0167	CbGeAlD
Nilotinib—MAPK14—mouth—cleft lip	0.00123	0.0166	CbGeAlD
Nilotinib—EPHB3—embryo—cleft lip	0.00114	0.0153	CbGeAlD
Nilotinib—MAPK8—telencephalon—cleft lip	0.00113	0.0151	CbGeAlD
Nilotinib—EPHA4—embryo—cleft lip	0.000955	0.0128	CbGeAlD
Nilotinib—EPHB3—telencephalon—cleft lip	0.000929	0.0125	CbGeAlD
Nilotinib—MAPK14—embryo—cleft lip	0.00088	0.0118	CbGeAlD
Nilotinib—EPHB2—head—cleft lip	0.000878	0.0118	CbGeAlD
Nilotinib—FGR—embryo—cleft lip	0.000877	0.0118	CbGeAlD
Nilotinib—HCK—telencephalon—cleft lip	0.000854	0.0115	CbGeAlD
Nilotinib—EPHA8—head—cleft lip	0.000842	0.0113	CbGeAlD
Nilotinib—KIT—mouth—cleft lip	0.000811	0.0109	CbGeAlD
Nilotinib—TEK—embryo—cleft lip	0.000798	0.0107	CbGeAlD
Nilotinib—MAPK11—head—cleft lip	0.000782	0.0105	CbGeAlD
Nilotinib—EPHA4—telencephalon—cleft lip	0.000776	0.0104	CbGeAlD
Nilotinib—CDC42BPB—head—cleft lip	0.000776	0.0104	CbGeAlD
Nilotinib—CA3—telencephalon—cleft lip	0.000767	0.0103	CbGeAlD
Nilotinib—EPHA3—head—cleft lip	0.000736	0.00988	CbGeAlD
Nilotinib—PDGFRA—embryo—cleft lip	0.000723	0.00971	CbGeAlD
Nilotinib—MAPK14—telencephalon—cleft lip	0.000716	0.00961	CbGeAlD
Nilotinib—MAPK8—head—cleft lip	0.000702	0.00942	CbGeAlD
Nilotinib—EPHA6—head—cleft lip	0.000702	0.00942	CbGeAlD
Nilotinib—CA14—telencephalon—cleft lip	0.000696	0.00935	CbGeAlD
Nilotinib—EPHB4—telencephalon—cleft lip	0.000679	0.00911	CbGeAlD
Nilotinib—TEK—telencephalon—cleft lip	0.000649	0.00872	CbGeAlD
Nilotinib—LYN—head—cleft lip	0.000648	0.0087	CbGeAlD
Nilotinib—CSF1R—embryo—cleft lip	0.000637	0.00855	CbGeAlD
Nilotinib—EPHB6—telencephalon—cleft lip	0.000621	0.00833	CbGeAlD
Nilotinib—TIE1—head—cleft lip	0.000609	0.00817	CbGeAlD
Nilotinib—PDGFRA—telencephalon—cleft lip	0.000588	0.0079	CbGeAlD
Nilotinib—EPHB3—head—cleft lip	0.000579	0.00777	CbGeAlD
Nilotinib—KIT—embryo—cleft lip	0.000578	0.00777	CbGeAlD
Nilotinib—PDGFRB—embryo—cleft lip	0.000565	0.00759	CbGeAlD
Nilotinib—CA12—telencephalon—cleft lip	0.000543	0.00729	CbGeAlD
Nilotinib—HCK—head—cleft lip	0.000532	0.00714	CbGeAlD
Nilotinib—MAP2K5—telencephalon—cleft lip	0.000531	0.00713	CbGeAlD
Nilotinib—CSF1R—telencephalon—cleft lip	0.000518	0.00696	CbGeAlD
Nilotinib—CA6—head—cleft lip	0.000504	0.00677	CbGeAlD
Nilotinib—ABL1—embryo—cleft lip	0.000503	0.00676	CbGeAlD
Nilotinib—EPHA4—head—cleft lip	0.000483	0.00649	CbGeAlD
Nilotinib—CA2—mouth—cleft lip	0.000481	0.00646	CbGeAlD
Nilotinib—CA3—head—cleft lip	0.000477	0.00641	CbGeAlD
Nilotinib—KIT—telencephalon—cleft lip	0.00047	0.00632	CbGeAlD
Nilotinib—PDGFRB—telencephalon—cleft lip	0.000459	0.00617	CbGeAlD
Nilotinib—MAPK14—head—cleft lip	0.000446	0.00599	CbGeAlD
Nilotinib—FGR—head—cleft lip	0.000444	0.00596	CbGeAlD
Nilotinib—CA1—telencephalon—cleft lip	0.00043	0.00578	CbGeAlD
Nilotinib—EPHA2—head—cleft lip	0.000415	0.00557	CbGeAlD
Nilotinib—ABL1—telencephalon—cleft lip	0.000409	0.0055	CbGeAlD
Nilotinib—TEK—head—cleft lip	0.000404	0.00543	CbGeAlD
Nilotinib—EPHB6—head—cleft lip	0.000386	0.00519	CbGeAlD
Nilotinib—PDGFRA—head—cleft lip	0.000366	0.00492	CbGeAlD
Nilotinib—CA2—embryo—cleft lip	0.000343	0.0046	CbGeAlD
Nilotinib—CA12—head—cleft lip	0.000338	0.00454	CbGeAlD
Nilotinib—CA4—telencephalon—cleft lip	0.000336	0.00452	CbGeAlD
Nilotinib—MAP2K5—head—cleft lip	0.00033	0.00444	CbGeAlD
Nilotinib—CSF1R—head—cleft lip	0.000323	0.00433	CbGeAlD
Nilotinib—KIT—head—cleft lip	0.000293	0.00393	CbGeAlD
Nilotinib—PDGFRB—head—cleft lip	0.000286	0.00384	CbGeAlD
Nilotinib—CA2—telencephalon—cleft lip	0.000279	0.00374	CbGeAlD
Nilotinib—CA1—head—cleft lip	0.000268	0.0036	CbGeAlD
Nilotinib—ABCG2—telencephalon—cleft lip	0.000258	0.00347	CbGeAlD
Nilotinib—ABL1—head—cleft lip	0.000255	0.00342	CbGeAlD
Nilotinib—CA4—head—cleft lip	0.000209	0.00281	CbGeAlD
Nilotinib—CYP2D6—telencephalon—cleft lip	0.000177	0.00238	CbGeAlD
Nilotinib—CA2—head—cleft lip	0.000174	0.00233	CbGeAlD
Nilotinib—ABCB1—embryo—cleft lip	0.000157	0.0021	CbGeAlD
Nilotinib—CYP2B6—head—cleft lip	0.000148	0.00199	CbGeAlD
Nilotinib—ABCB1—telencephalon—cleft lip	0.000127	0.00171	CbGeAlD
Nilotinib—CYP2D6—head—cleft lip	0.00011	0.00148	CbGeAlD
Nilotinib—ABCB1—head—cleft lip	7.93e-05	0.00106	CbGeAlD
Nilotinib—BRAF—Signaling Pathways—FGF3—cleft lip	1.03e-05	6.01e-05	CbGpPWpGaD
Nilotinib—LYN—Hemostasis—NOS3—cleft lip	1.03e-05	5.97e-05	CbGpPWpGaD
Nilotinib—MAP2K5—Signaling Pathways—FGF10—cleft lip	1.02e-05	5.95e-05	CbGpPWpGaD
Nilotinib—ABL1—Hemostasis—NOS3—cleft lip	1.02e-05	5.94e-05	CbGpPWpGaD
Nilotinib—PDGFRB—Immune System—FGF10—cleft lip	1.02e-05	5.93e-05	CbGpPWpGaD
Nilotinib—PDGFRA—Adaptive Immune System—FGF2—cleft lip	1.02e-05	5.93e-05	CbGpPWpGaD
Nilotinib—MAPK11—Signaling Pathways—FGF9—cleft lip	1.02e-05	5.91e-05	CbGpPWpGaD
Nilotinib—CA12—Metabolism—NOS3—cleft lip	1.01e-05	5.9e-05	CbGpPWpGaD
Nilotinib—LCK—Adaptive Immune System—FGFR1—cleft lip	1.01e-05	5.87e-05	CbGpPWpGaD
Nilotinib—BRAF—Signaling Pathways—FGF9—cleft lip	1.01e-05	5.86e-05	CbGpPWpGaD
Nilotinib—MAPK14—Developmental Biology—FGF2—cleft lip	1.01e-05	5.85e-05	CbGpPWpGaD
Nilotinib—HCK—Immune System—FGF2—cleft lip	1e-05	5.84e-05	CbGpPWpGaD
Nilotinib—LYN—Immune System—FGF10—cleft lip	9.99e-06	5.81e-05	CbGpPWpGaD
Nilotinib—LCK—Immune System—FGF3—cleft lip	9.95e-06	5.79e-05	CbGpPWpGaD
Nilotinib—ABL1—Immune System—FGF10—cleft lip	9.94e-06	5.78e-05	CbGpPWpGaD
Nilotinib—LCK—Innate Immune System—FGFR3—cleft lip	9.94e-06	5.78e-05	CbGpPWpGaD
Nilotinib—MAPK11—Immune System—FGFR1—cleft lip	9.92e-06	5.77e-05	CbGpPWpGaD
Nilotinib—MAPK14—Signaling Pathways—SPRY2—cleft lip	9.91e-06	5.76e-05	CbGpPWpGaD
Nilotinib—MAPK14—Signaling Pathways—FGF7—cleft lip	9.91e-06	5.76e-05	CbGpPWpGaD
Nilotinib—PDGFRB—Signaling Pathways—FGF8—cleft lip	9.85e-06	5.73e-05	CbGpPWpGaD
Nilotinib—PDGFRA—Signaling Pathways—PTCH1—cleft lip	9.82e-06	5.71e-05	CbGpPWpGaD
Nilotinib—ABCB1—Integrated Pancreatic Cancer Pathway—FGF2—cleft lip	9.74e-06	5.66e-05	CbGpPWpGaD
Nilotinib—BRAF—Disease—FGFR2—cleft lip	9.74e-06	5.66e-05	CbGpPWpGaD
Nilotinib—MAPK14—Hemostasis—NOS3—cleft lip	9.73e-06	5.66e-05	CbGpPWpGaD
Nilotinib—LCK—Immune System—FGF9—cleft lip	9.71e-06	5.64e-05	CbGpPWpGaD
Nilotinib—LYN—Signaling Pathways—FGF8—cleft lip	9.65e-06	5.61e-05	CbGpPWpGaD
Nilotinib—KIT—Immune System—FGFR2—cleft lip	9.6e-06	5.58e-05	CbGpPWpGaD
Nilotinib—PDGFRB—Innate Immune System—FGF2—cleft lip	9.57e-06	5.56e-05	CbGpPWpGaD
Nilotinib—CYP2C8—Metabolism—SLC19A1—cleft lip	9.56e-06	5.56e-05	CbGpPWpGaD
Nilotinib—LCK—Adaptive Immune System—FGFR3—cleft lip	9.54e-06	5.55e-05	CbGpPWpGaD
Nilotinib—MAPK14—Immune System—FGF10—cleft lip	9.47e-06	5.51e-05	CbGpPWpGaD
Nilotinib—PDGFRB—Disease—FGF10—cleft lip	9.42e-06	5.48e-05	CbGpPWpGaD
Nilotinib—KIT—Signaling Pathways—FGF3—cleft lip	9.4e-06	5.47e-05	CbGpPWpGaD
Nilotinib—MAPK11—Immune System—FGFR3—cleft lip	9.38e-06	5.45e-05	CbGpPWpGaD
Nilotinib—BRAF—Disease—MTHFR—cleft lip	9.37e-06	5.45e-05	CbGpPWpGaD
Nilotinib—CA9—Metabolism—MTHFR—cleft lip	9.37e-06	5.45e-05	CbGpPWpGaD
Nilotinib—LYN—Innate Immune System—FGF2—cleft lip	9.37e-06	5.45e-05	CbGpPWpGaD
Nilotinib—CYP2B6—Metabolism—TCN2—cleft lip	9.36e-06	5.44e-05	CbGpPWpGaD
Nilotinib—ABL1—Innate Immune System—FGF2—cleft lip	9.32e-06	5.42e-05	CbGpPWpGaD
Nilotinib—HCK—Disease—FGF2—cleft lip	9.27e-06	5.39e-05	CbGpPWpGaD
Nilotinib—LCK—Disease—FGF3—cleft lip	9.19e-06	5.34e-05	CbGpPWpGaD
Nilotinib—PDGFRB—Adaptive Immune System—FGF2—cleft lip	9.19e-06	5.34e-05	CbGpPWpGaD
Nilotinib—KIT—Signaling Pathways—FGF9—cleft lip	9.17e-06	5.33e-05	CbGpPWpGaD
Nilotinib—MAPK14—Signaling Pathways—FGF8—cleft lip	9.14e-06	5.32e-05	CbGpPWpGaD
Nilotinib—HCK—Disease—NOS3—cleft lip	9.14e-06	5.32e-05	CbGpPWpGaD
Nilotinib—MAPK8—Immune System—FGF2—cleft lip	9.1e-06	5.29e-05	CbGpPWpGaD
Nilotinib—BLK—Immune System—FGF2—cleft lip	9.1e-06	5.29e-05	CbGpPWpGaD
Nilotinib—PDGFRA—Immune System—FGFR2—cleft lip	9.09e-06	5.28e-05	CbGpPWpGaD
Nilotinib—BRAF—Disease—FGFR1—cleft lip	9.08e-06	5.28e-05	CbGpPWpGaD
Nilotinib—FGR—Immune System—FGF2—cleft lip	9.07e-06	5.27e-05	CbGpPWpGaD
Nilotinib—LYN—Adaptive Immune System—FGF2—cleft lip	9e-06	5.23e-05	CbGpPWpGaD
Nilotinib—LCK—Disease—FGF9—cleft lip	8.96e-06	5.21e-05	CbGpPWpGaD
Nilotinib—KIT—Immune System—FGFR1—cleft lip	8.95e-06	5.2e-05	CbGpPWpGaD
Nilotinib—PDGFRA—Signaling Pathways—FGF3—cleft lip	8.9e-06	5.18e-05	CbGpPWpGaD
Nilotinib—MAPK14—Innate Immune System—FGF2—cleft lip	8.88e-06	5.16e-05	CbGpPWpGaD
Nilotinib—KIT—Disease—FGFR2—cleft lip	8.86e-06	5.15e-05	CbGpPWpGaD
Nilotinib—ABCG2—Metabolism—MTR—cleft lip	8.85e-06	5.14e-05	CbGpPWpGaD
Nilotinib—PDGFRB—Signaling Pathways—PTCH1—cleft lip	8.85e-06	5.14e-05	CbGpPWpGaD
Nilotinib—PDGFRA—Signaling Pathways—FGF9—cleft lip	8.68e-06	5.05e-05	CbGpPWpGaD
Nilotinib—LYN—Signaling Pathways—PTCH1—cleft lip	8.66e-06	5.04e-05	CbGpPWpGaD
Nilotinib—MAPK8—Signaling Pathways—FGFR2—cleft lip	8.64e-06	5.02e-05	CbGpPWpGaD
Nilotinib—BRAF—Disease—FGFR3—cleft lip	8.58e-06	4.99e-05	CbGpPWpGaD
Nilotinib—MAPK11—Signaling Pathways—FGF10—cleft lip	8.58e-06	4.99e-05	CbGpPWpGaD
Nilotinib—LCK—Signaling Pathways—SPRY2—cleft lip	8.57e-06	4.98e-05	CbGpPWpGaD
Nilotinib—LCK—Signaling Pathways—FGF7—cleft lip	8.57e-06	4.98e-05	CbGpPWpGaD
Nilotinib—KIT—Disease—MTHFR—cleft lip	8.53e-06	4.96e-05	CbGpPWpGaD
Nilotinib—BRAF—Signaling Pathways—FGF10—cleft lip	8.5e-06	4.94e-05	CbGpPWpGaD
Nilotinib—PDGFRA—Immune System—FGFR1—cleft lip	8.47e-06	4.93e-05	CbGpPWpGaD
Nilotinib—KIT—Immune System—FGFR3—cleft lip	8.46e-06	4.92e-05	CbGpPWpGaD
Nilotinib—LCK—Hemostasis—NOS3—cleft lip	8.41e-06	4.89e-05	CbGpPWpGaD
Nilotinib—PDGFRA—Disease—FGFR2—cleft lip	8.39e-06	4.88e-05	CbGpPWpGaD
Nilotinib—ABCB1—Metabolism—SLC19A1—cleft lip	8.33e-06	4.84e-05	CbGpPWpGaD
Nilotinib—KIT—Disease—FGFR1—cleft lip	8.26e-06	4.8e-05	CbGpPWpGaD
Nilotinib—MAP2K5—Signaling Pathways—FGFR2—cleft lip	8.21e-06	4.78e-05	CbGpPWpGaD
Nilotinib—MAPK14—Signaling Pathways—PTCH1—cleft lip	8.21e-06	4.77e-05	CbGpPWpGaD
Nilotinib—LCK—Immune System—FGF10—cleft lip	8.19e-06	4.76e-05	CbGpPWpGaD
Nilotinib—PDGFRB—Immune System—FGFR2—cleft lip	8.19e-06	4.76e-05	CbGpPWpGaD
Nilotinib—CA4—Metabolism—NOS3—cleft lip	8.09e-06	4.7e-05	CbGpPWpGaD
Nilotinib—PDGFRA—Disease—MTHFR—cleft lip	8.08e-06	4.7e-05	CbGpPWpGaD
Nilotinib—MAPK8—Signaling Pathways—FGFR1—cleft lip	8.05e-06	4.68e-05	CbGpPWpGaD
Nilotinib—PDGFRB—Signaling Pathways—FGF3—cleft lip	8.02e-06	4.66e-05	CbGpPWpGaD
Nilotinib—LYN—Immune System—FGFR2—cleft lip	8.01e-06	4.66e-05	CbGpPWpGaD
Nilotinib—PDGFRA—Immune System—FGFR3—cleft lip	8e-06	4.66e-05	CbGpPWpGaD
Nilotinib—ABL1—Immune System—FGFR2—cleft lip	7.98e-06	4.64e-05	CbGpPWpGaD
Nilotinib—CYP2C8—Metabolism—TCN2—cleft lip	7.92e-06	4.61e-05	CbGpPWpGaD
Nilotinib—LCK—Signaling Pathways—FGF8—cleft lip	7.91e-06	4.6e-05	CbGpPWpGaD
Nilotinib—LYN—Signaling Pathways—FGF3—cleft lip	7.85e-06	4.57e-05	CbGpPWpGaD
Nilotinib—CYP2D6—Metabolism—SLC19A1—cleft lip	7.85e-06	4.56e-05	CbGpPWpGaD
Nilotinib—PDGFRA—Disease—FGFR1—cleft lip	7.82e-06	4.55e-05	CbGpPWpGaD
Nilotinib—PDGFRB—Signaling Pathways—FGF9—cleft lip	7.82e-06	4.55e-05	CbGpPWpGaD
Nilotinib—KIT—Disease—FGFR3—cleft lip	7.81e-06	4.54e-05	CbGpPWpGaD
Nilotinib—CYP2C9—Metabolism—SLC19A1—cleft lip	7.78e-06	4.52e-05	CbGpPWpGaD
Nilotinib—CA2—Metabolism—NOS3—cleft lip	7.76e-06	4.51e-05	CbGpPWpGaD
Nilotinib—KIT—Signaling Pathways—FGF10—cleft lip	7.73e-06	4.5e-05	CbGpPWpGaD
Nilotinib—LCK—Innate Immune System—FGF2—cleft lip	7.68e-06	4.47e-05	CbGpPWpGaD
Nilotinib—LYN—Signaling Pathways—FGF9—cleft lip	7.66e-06	4.45e-05	CbGpPWpGaD
Nilotinib—MAP2K5—Signaling Pathways—FGFR1—cleft lip	7.66e-06	4.45e-05	CbGpPWpGaD
Nilotinib—PDGFRB—Immune System—FGFR1—cleft lip	7.63e-06	4.44e-05	CbGpPWpGaD
Nilotinib—MAPK8—Signaling Pathways—FGFR3—cleft lip	7.61e-06	4.43e-05	CbGpPWpGaD
Nilotinib—MAPK14—Immune System—FGFR2—cleft lip	7.6e-06	4.42e-05	CbGpPWpGaD
Nilotinib—LCK—Disease—FGF10—cleft lip	7.56e-06	4.4e-05	CbGpPWpGaD
Nilotinib—PDGFRB—Disease—FGFR2—cleft lip	7.56e-06	4.4e-05	CbGpPWpGaD
Nilotinib—LYN—Immune System—FGFR1—cleft lip	7.47e-06	4.34e-05	CbGpPWpGaD
Nilotinib—MAPK14—Signaling Pathways—FGF3—cleft lip	7.44e-06	4.33e-05	CbGpPWpGaD
Nilotinib—CA1—Metabolism—NOS3—cleft lip	7.44e-06	4.32e-05	CbGpPWpGaD
Nilotinib—ABL1—Immune System—FGFR1—cleft lip	7.44e-06	4.32e-05	CbGpPWpGaD
Nilotinib—PDGFRA—Disease—FGFR3—cleft lip	7.39e-06	4.3e-05	CbGpPWpGaD
Nilotinib—LCK—Adaptive Immune System—FGF2—cleft lip	7.37e-06	4.29e-05	CbGpPWpGaD
Nilotinib—PDGFRA—Signaling Pathways—FGF10—cleft lip	7.32e-06	4.26e-05	CbGpPWpGaD
Nilotinib—PDGFRB—Disease—MTHFR—cleft lip	7.28e-06	4.23e-05	CbGpPWpGaD
Nilotinib—MAPK14—Signaling Pathways—FGF9—cleft lip	7.26e-06	4.22e-05	CbGpPWpGaD
Nilotinib—MAPK11—Immune System—FGF2—cleft lip	7.25e-06	4.21e-05	CbGpPWpGaD
Nilotinib—MAP2K5—Signaling Pathways—FGFR3—cleft lip	7.24e-06	4.21e-05	CbGpPWpGaD
Nilotinib—PDGFRB—Immune System—FGFR3—cleft lip	7.21e-06	4.19e-05	CbGpPWpGaD
Nilotinib—LCK—Signaling Pathways—PTCH1—cleft lip	7.1e-06	4.13e-05	CbGpPWpGaD
Nilotinib—MAPK14—Immune System—FGFR1—cleft lip	7.08e-06	4.12e-05	CbGpPWpGaD
Nilotinib—LYN—Immune System—FGFR3—cleft lip	7.06e-06	4.11e-05	CbGpPWpGaD
Nilotinib—PDGFRB—Disease—FGFR1—cleft lip	7.04e-06	4.1e-05	CbGpPWpGaD
Nilotinib—ABL1—Immune System—FGFR3—cleft lip	7.03e-06	4.09e-05	CbGpPWpGaD
Nilotinib—ABCB1—Metabolism—TCN2—cleft lip	6.9e-06	4.01e-05	CbGpPWpGaD
Nilotinib—MAPK11—Signaling Pathways—FGFR2—cleft lip	6.88e-06	4e-05	CbGpPWpGaD
Nilotinib—BRAF—Signaling Pathways—FGFR2—cleft lip	6.82e-06	3.97e-05	CbGpPWpGaD
Nilotinib—MAPK14—Immune System—FGFR3—cleft lip	6.69e-06	3.89e-05	CbGpPWpGaD
Nilotinib—PDGFRB—Disease—FGFR3—cleft lip	6.66e-06	3.87e-05	CbGpPWpGaD
Nilotinib—BRAF—Disease—FGF2—cleft lip	6.63e-06	3.85e-05	CbGpPWpGaD
Nilotinib—PDGFRB—Signaling Pathways—FGF10—cleft lip	6.6e-06	3.84e-05	CbGpPWpGaD
Nilotinib—LCK—Immune System—FGFR2—cleft lip	6.57e-06	3.82e-05	CbGpPWpGaD
Nilotinib—BRAF—Disease—NOS3—cleft lip	6.54e-06	3.8e-05	CbGpPWpGaD
Nilotinib—CA9—Metabolism—NOS3—cleft lip	6.54e-06	3.8e-05	CbGpPWpGaD
Nilotinib—KIT—Immune System—FGF2—cleft lip	6.53e-06	3.8e-05	CbGpPWpGaD
Nilotinib—CYP2D6—Metabolism—TCN2—cleft lip	6.5e-06	3.78e-05	CbGpPWpGaD
Nilotinib—CYP2B6—Metabolism—MTR—cleft lip	6.48e-06	3.77e-05	CbGpPWpGaD
Nilotinib—LYN—Signaling Pathways—FGF10—cleft lip	6.46e-06	3.76e-05	CbGpPWpGaD
Nilotinib—CYP2C9—Metabolism—TCN2—cleft lip	6.45e-06	3.75e-05	CbGpPWpGaD
Nilotinib—LCK—Signaling Pathways—FGF3—cleft lip	6.44e-06	3.74e-05	CbGpPWpGaD
Nilotinib—MAPK11—Signaling Pathways—FGFR1—cleft lip	6.42e-06	3.73e-05	CbGpPWpGaD
Nilotinib—UGT1A1—Metabolism—TYMS—cleft lip	6.39e-06	3.72e-05	CbGpPWpGaD
Nilotinib—ABCB1—Integrated Pancreatic Cancer Pathway—MYC—cleft lip	6.37e-06	3.7e-05	CbGpPWpGaD
Nilotinib—BRAF—Signaling Pathways—FGFR1—cleft lip	6.36e-06	3.7e-05	CbGpPWpGaD
Nilotinib—LCK—Signaling Pathways—FGF9—cleft lip	6.28e-06	3.65e-05	CbGpPWpGaD
Nilotinib—KIT—Signaling Pathways—FGFR2—cleft lip	6.21e-06	3.61e-05	CbGpPWpGaD
Nilotinib—PDGFRA—Immune System—FGF2—cleft lip	6.19e-06	3.6e-05	CbGpPWpGaD
Nilotinib—LCK—Immune System—FGFR1—cleft lip	6.12e-06	3.56e-05	CbGpPWpGaD
Nilotinib—MAPK14—Signaling Pathways—FGF10—cleft lip	6.12e-06	3.56e-05	CbGpPWpGaD
Nilotinib—LCK—Disease—FGFR2—cleft lip	6.07e-06	3.53e-05	CbGpPWpGaD
Nilotinib—MAPK11—Signaling Pathways—FGFR3—cleft lip	6.06e-06	3.53e-05	CbGpPWpGaD
Nilotinib—HCK—Disease—MYC—cleft lip	6.06e-06	3.52e-05	CbGpPWpGaD
Nilotinib—KIT—Disease—FGF2—cleft lip	6.03e-06	3.51e-05	CbGpPWpGaD
Nilotinib—BRAF—Signaling Pathways—FGFR3—cleft lip	6.01e-06	3.49e-05	CbGpPWpGaD
Nilotinib—KIT—Disease—NOS3—cleft lip	5.95e-06	3.46e-05	CbGpPWpGaD
Nilotinib—MAPK8—Signaling Pathways—FGF2—cleft lip	5.88e-06	3.42e-05	CbGpPWpGaD
Nilotinib—PDGFRA—Signaling Pathways—FGFR2—cleft lip	5.87e-06	3.42e-05	CbGpPWpGaD
Nilotinib—LCK—Disease—MTHFR—cleft lip	5.84e-06	3.4e-05	CbGpPWpGaD
Nilotinib—MAPK8—Signaling Pathways—NOS3—cleft lip	5.8e-06	3.37e-05	CbGpPWpGaD
Nilotinib—LCK—Immune System—FGFR3—cleft lip	5.79e-06	3.37e-05	CbGpPWpGaD
Nilotinib—KIT—Signaling Pathways—FGFR1—cleft lip	5.78e-06	3.36e-05	CbGpPWpGaD
Nilotinib—PDGFRA—Disease—FGF2—cleft lip	5.71e-06	3.32e-05	CbGpPWpGaD
Nilotinib—LCK—Disease—FGFR1—cleft lip	5.65e-06	3.29e-05	CbGpPWpGaD
Nilotinib—PDGFRA—Disease—NOS3—cleft lip	5.63e-06	3.28e-05	CbGpPWpGaD
Nilotinib—MAP2K5—Signaling Pathways—FGF2—cleft lip	5.59e-06	3.25e-05	CbGpPWpGaD
Nilotinib—UGT1A1—Metabolism—MTHFR—cleft lip	5.58e-06	3.25e-05	CbGpPWpGaD
Nilotinib—PDGFRB—Immune System—FGF2—cleft lip	5.57e-06	3.24e-05	CbGpPWpGaD
Nilotinib—MAP2K5—Signaling Pathways—NOS3—cleft lip	5.51e-06	3.21e-05	CbGpPWpGaD
Nilotinib—CYP2C8—Metabolism—MTR—cleft lip	5.49e-06	3.19e-05	CbGpPWpGaD
Nilotinib—PDGFRA—Signaling Pathways—FGFR1—cleft lip	5.48e-06	3.18e-05	CbGpPWpGaD
Nilotinib—KIT—Signaling Pathways—FGFR3—cleft lip	5.47e-06	3.18e-05	CbGpPWpGaD
Nilotinib—LYN—Immune System—FGF2—cleft lip	5.46e-06	3.17e-05	CbGpPWpGaD
Nilotinib—ABL1—Immune System—FGF2—cleft lip	5.43e-06	3.16e-05	CbGpPWpGaD
Nilotinib—ABCG2—Metabolism—TYMS—cleft lip	5.42e-06	3.15e-05	CbGpPWpGaD
Nilotinib—LCK—Disease—FGFR3—cleft lip	5.34e-06	3.11e-05	CbGpPWpGaD
Nilotinib—LCK—Signaling Pathways—FGF10—cleft lip	5.29e-06	3.08e-05	CbGpPWpGaD
Nilotinib—PDGFRB—Signaling Pathways—FGFR2—cleft lip	5.29e-06	3.08e-05	CbGpPWpGaD
Nilotinib—LYN—Signaling Pathways—FGFR2—cleft lip	5.18e-06	3.01e-05	CbGpPWpGaD
Nilotinib—PDGFRA—Signaling Pathways—FGFR3—cleft lip	5.18e-06	3.01e-05	CbGpPWpGaD
Nilotinib—MAPK14—Immune System—FGF2—cleft lip	5.17e-06	3.01e-05	CbGpPWpGaD
Nilotinib—PDGFRB—Disease—FGF2—cleft lip	5.15e-06	2.99e-05	CbGpPWpGaD
Nilotinib—CYP3A4—Metabolism—SLC19A1—cleft lip	5.13e-06	2.98e-05	CbGpPWpGaD
Nilotinib—PDGFRB—Disease—NOS3—cleft lip	5.07e-06	2.95e-05	CbGpPWpGaD
Nilotinib—PDGFRB—Signaling Pathways—FGFR1—cleft lip	4.93e-06	2.87e-05	CbGpPWpGaD
Nilotinib—MAPK14—Signaling Pathways—FGFR2—cleft lip	4.91e-06	2.86e-05	CbGpPWpGaD
Nilotinib—LYN—Signaling Pathways—FGFR1—cleft lip	4.83e-06	2.81e-05	CbGpPWpGaD
Nilotinib—ABCB1—Metabolism—MTR—cleft lip	4.78e-06	2.78e-05	CbGpPWpGaD
Nilotinib—ABCG2—Metabolism—MTHFR—cleft lip	4.74e-06	2.75e-05	CbGpPWpGaD
Nilotinib—MAPK11—Gene Expression—MYC—cleft lip	4.71e-06	2.74e-05	CbGpPWpGaD
Nilotinib—MAPK11—Signaling Pathways—FGF2—cleft lip	4.69e-06	2.72e-05	CbGpPWpGaD
Nilotinib—PDGFRB—Signaling Pathways—FGFR3—cleft lip	4.66e-06	2.71e-05	CbGpPWpGaD
Nilotinib—BRAF—Signaling Pathways—FGF2—cleft lip	4.64e-06	2.7e-05	CbGpPWpGaD
Nilotinib—MAPK11—Signaling Pathways—NOS3—cleft lip	4.62e-06	2.69e-05	CbGpPWpGaD
Nilotinib—MAPK14—Signaling Pathways—FGFR1—cleft lip	4.58e-06	2.66e-05	CbGpPWpGaD
Nilotinib—BRAF—Signaling Pathways—NOS3—cleft lip	4.58e-06	2.66e-05	CbGpPWpGaD
Nilotinib—LYN—Signaling Pathways—FGFR3—cleft lip	4.56e-06	2.65e-05	CbGpPWpGaD
Nilotinib—CYP2D6—Metabolism—MTR—cleft lip	4.51e-06	2.62e-05	CbGpPWpGaD
Nilotinib—LCK—Immune System—FGF2—cleft lip	4.47e-06	2.6e-05	CbGpPWpGaD
Nilotinib—CYP2C9—Metabolism—MTR—cleft lip	4.47e-06	2.6e-05	CbGpPWpGaD
Nilotinib—BRAF—Disease—MYC—cleft lip	4.33e-06	2.52e-05	CbGpPWpGaD
Nilotinib—MAPK14—Signaling Pathways—FGFR3—cleft lip	4.33e-06	2.52e-05	CbGpPWpGaD
Nilotinib—CYP3A4—Metabolism—TCN2—cleft lip	4.25e-06	2.47e-05	CbGpPWpGaD
Nilotinib—LCK—Signaling Pathways—FGFR2—cleft lip	4.25e-06	2.47e-05	CbGpPWpGaD
Nilotinib—KIT—Signaling Pathways—FGF2—cleft lip	4.22e-06	2.46e-05	CbGpPWpGaD
Nilotinib—KIT—Signaling Pathways—NOS3—cleft lip	4.17e-06	2.42e-05	CbGpPWpGaD
Nilotinib—LCK—Disease—FGF2—cleft lip	4.13e-06	2.4e-05	CbGpPWpGaD
Nilotinib—LCK—Disease—NOS3—cleft lip	4.07e-06	2.37e-05	CbGpPWpGaD
Nilotinib—PDGFRA—Signaling Pathways—FGF2—cleft lip	4e-06	2.33e-05	CbGpPWpGaD
Nilotinib—CYP2B6—Metabolism—TYMS—cleft lip	3.97e-06	2.31e-05	CbGpPWpGaD
Nilotinib—LCK—Signaling Pathways—FGFR1—cleft lip	3.96e-06	2.3e-05	CbGpPWpGaD
Nilotinib—PDGFRA—Signaling Pathways—NOS3—cleft lip	3.94e-06	2.29e-05	CbGpPWpGaD
Nilotinib—KIT—Disease—MYC—cleft lip	3.94e-06	2.29e-05	CbGpPWpGaD
Nilotinib—UGT1A1—Metabolism—NOS3—cleft lip	3.89e-06	2.26e-05	CbGpPWpGaD
Nilotinib—MAPK8—Signaling Pathways—MYC—cleft lip	3.84e-06	2.24e-05	CbGpPWpGaD
Nilotinib—LCK—Signaling Pathways—FGFR3—cleft lip	3.74e-06	2.18e-05	CbGpPWpGaD
Nilotinib—PDGFRA—Disease—MYC—cleft lip	3.73e-06	2.17e-05	CbGpPWpGaD
Nilotinib—MAP2K5—Signaling Pathways—MYC—cleft lip	3.66e-06	2.13e-05	CbGpPWpGaD
Nilotinib—PDGFRB—Signaling Pathways—FGF2—cleft lip	3.6e-06	2.1e-05	CbGpPWpGaD
Nilotinib—PDGFRB—Signaling Pathways—NOS3—cleft lip	3.55e-06	2.07e-05	CbGpPWpGaD
Nilotinib—LYN—Signaling Pathways—FGF2—cleft lip	3.53e-06	2.05e-05	CbGpPWpGaD
Nilotinib—LYN—Signaling Pathways—NOS3—cleft lip	3.48e-06	2.02e-05	CbGpPWpGaD
Nilotinib—CYP2B6—Metabolism—MTHFR—cleft lip	3.47e-06	2.02e-05	CbGpPWpGaD
Nilotinib—CYP2C8—Metabolism—TYMS—cleft lip	3.36e-06	1.96e-05	CbGpPWpGaD
Nilotinib—PDGFRB—Disease—MYC—cleft lip	3.36e-06	1.96e-05	CbGpPWpGaD
Nilotinib—MAPK14—Gene Expression—MYC—cleft lip	3.36e-06	1.96e-05	CbGpPWpGaD
Nilotinib—MAPK14—Signaling Pathways—FGF2—cleft lip	3.34e-06	1.94e-05	CbGpPWpGaD
Nilotinib—ABCG2—Metabolism—NOS3—cleft lip	3.3e-06	1.92e-05	CbGpPWpGaD
Nilotinib—MAPK14—Signaling Pathways—NOS3—cleft lip	3.3e-06	1.92e-05	CbGpPWpGaD
Nilotinib—MAPK11—Signaling Pathways—MYC—cleft lip	3.06e-06	1.78e-05	CbGpPWpGaD
Nilotinib—BRAF—Signaling Pathways—MYC—cleft lip	3.03e-06	1.76e-05	CbGpPWpGaD
Nilotinib—CYP3A4—Metabolism—MTR—cleft lip	2.95e-06	1.71e-05	CbGpPWpGaD
Nilotinib—CYP2C8—Metabolism—MTHFR—cleft lip	2.94e-06	1.71e-05	CbGpPWpGaD
Nilotinib—ABCB1—Metabolism—TYMS—cleft lip	2.93e-06	1.7e-05	CbGpPWpGaD
Nilotinib—LCK—Signaling Pathways—FGF2—cleft lip	2.89e-06	1.68e-05	CbGpPWpGaD
Nilotinib—LCK—Signaling Pathways—NOS3—cleft lip	2.85e-06	1.66e-05	CbGpPWpGaD
Nilotinib—CYP2D6—Metabolism—TYMS—cleft lip	2.76e-06	1.61e-05	CbGpPWpGaD
Nilotinib—KIT—Signaling Pathways—MYC—cleft lip	2.76e-06	1.61e-05	CbGpPWpGaD
Nilotinib—CYP2C9—Metabolism—TYMS—cleft lip	2.74e-06	1.59e-05	CbGpPWpGaD
Nilotinib—LCK—Disease—MYC—cleft lip	2.7e-06	1.57e-05	CbGpPWpGaD
Nilotinib—PDGFRA—Signaling Pathways—MYC—cleft lip	2.61e-06	1.52e-05	CbGpPWpGaD
Nilotinib—ABCB1—Metabolism—MTHFR—cleft lip	2.56e-06	1.49e-05	CbGpPWpGaD
Nilotinib—CYP2B6—Metabolism—NOS3—cleft lip	2.42e-06	1.41e-05	CbGpPWpGaD
Nilotinib—CYP2D6—Metabolism—MTHFR—cleft lip	2.41e-06	1.4e-05	CbGpPWpGaD
Nilotinib—CYP2C9—Metabolism—MTHFR—cleft lip	2.39e-06	1.39e-05	CbGpPWpGaD
Nilotinib—PDGFRB—Signaling Pathways—MYC—cleft lip	2.36e-06	1.37e-05	CbGpPWpGaD
Nilotinib—LYN—Signaling Pathways—MYC—cleft lip	2.31e-06	1.34e-05	CbGpPWpGaD
Nilotinib—MAPK14—Signaling Pathways—MYC—cleft lip	2.19e-06	1.27e-05	CbGpPWpGaD
Nilotinib—CYP2C8—Metabolism—NOS3—cleft lip	2.05e-06	1.19e-05	CbGpPWpGaD
Nilotinib—LCK—Signaling Pathways—MYC—cleft lip	1.89e-06	1.1e-05	CbGpPWpGaD
Nilotinib—CYP3A4—Metabolism—TYMS—cleft lip	1.81e-06	1.05e-05	CbGpPWpGaD
Nilotinib—ABCB1—Metabolism—NOS3—cleft lip	1.79e-06	1.04e-05	CbGpPWpGaD
Nilotinib—CYP2D6—Metabolism—NOS3—cleft lip	1.68e-06	9.79e-06	CbGpPWpGaD
Nilotinib—CYP2C9—Metabolism—NOS3—cleft lip	1.67e-06	9.7e-06	CbGpPWpGaD
Nilotinib—CYP3A4—Metabolism—MTHFR—cleft lip	1.58e-06	9.18e-06	CbGpPWpGaD
Nilotinib—CYP3A4—Metabolism—NOS3—cleft lip	1.1e-06	6.4e-06	CbGpPWpGaD
